GlassScriptPhysician profile
Rodney Prater
NPI 1477838944
$2,708.67
in general payments reported to CMS, 2019-2025
17 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $614 · 2023: $610 · 2024: $570 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,626.02 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $378.53 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $346.80 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $343.86 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $295.33 | 2023-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $256.52 | 2021-2024 | |
| Alkermes, INC. | $162.32 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $157.42 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $155.74 | 2022-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $148.88 | 2021-2024 | Trintellix |
| Acadia Pharmaceuticals INC | $117.93 | 2025 | Nuplazid |
| Vanda Pharmaceuticals INC. | $116.89 | 2022-2024 | Fanapt, Hetlioz |
| Tris Pharma INC | $85.03 | 2022-2024 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $36.43 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $35.29 | 2022 | |
| Idorsia Pharmaceuticals US INC | $34.40 | 2023-2024 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $20.21 | 2022 | |
| Eisai INC. | $17.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Prater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.